Patents by Inventor Virginia Ammendola

Virginia Ammendola has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220275397
    Abstract: The present invention relates to isolated polynucleotide and polypeptide sequences derived from novel chimpanzee adenovirus ChAd157, as well as to recombinant polynucleotides, vectors, adenoviruses, cells and compositions comprising said polynucleotide and polypeptide sequences.
    Type: Application
    Filed: May 11, 2022
    Publication date: September 1, 2022
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Virginia AMMENDOLA, Stefania CAPONE, Stefano COLLOCA, Antonella FOLGORI, Rossella MERONE
  • Patent number: 11414679
    Abstract: The present invention relates to isolated polynucleotide and polypeptide sequences derived from novel chimpanzee adenovirus ChAd157, as well as to recombinant polynucleotides, vectors, adenoviruses, cells and compositions comprising said polynucleotide and polypeptide sequences.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: August 16, 2022
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Virginia Ammendola, Stefania Capone, Stefano Colloca, Antonella Folgori, Rossella Merone
  • Publication number: 20220220157
    Abstract: There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of: (a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, (b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and (c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.
    Type: Application
    Filed: January 25, 2022
    Publication date: July 14, 2022
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Virginia AMMENDOLA, Stefano COLLOCA, Riccardo CORTESE, Fabiana GRAZIOLI, Alfredo NICOSIA, Alessandra VITELLI
  • Publication number: 20220204566
    Abstract: There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of: (a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, (b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and (c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.
    Type: Application
    Filed: December 30, 2021
    Publication date: June 30, 2022
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Stefano COLLOCA, Virginia AMMENDOLA, Fabiana GRAZIOLI, Alessandra Franz VITELLI, Alfredo NICOSIA, Riccardo CORTESE
  • Publication number: 20220112245
    Abstract: The invention provides adenoviral vectors comprising transgenes encoding Lyssaviral antigens. The vectors can be used to produce vaccines for the prophylaxis, amelioration and treatment of diseases caused by Lyssaviral diseases, e.g., rabies.
    Type: Application
    Filed: December 8, 2017
    Publication date: April 14, 2022
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Virginia AMMENDOLA, Stefano COLLOCA, Alessandra VITELLI, Benjamin WIZEL
  • Patent number: 11268108
    Abstract: Replication competent simian adenoviral vectors are provided for the delivery of exogenous immunogens. Vectors of the invention demonstrate superior replication and expression of exogenous immunogens. They are useful as prophylactic and therapeutic vaccines as well as in gene therapy.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: March 8, 2022
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Virginia Ammendola, Stefano Colloca, Alessandra Vitelli
  • Publication number: 20220064669
    Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).
    Type: Application
    Filed: July 30, 2021
    Publication date: March 3, 2022
    Inventors: Nancy J. Sullivan, Gary J. Nabel, Clement Asiedu, Cheng Cheng, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Stefano Colloca
  • Patent number: 11254710
    Abstract: There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of: (a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, (b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and (c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: February 22, 2022
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Stefano Colloca, Virginia Ammendola, Fabiana Grazioli, Alessandra Franz Vitelli, Alfredo Nicosia, Riccardo Cortese
  • Patent number: 11254711
    Abstract: There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of: (a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, (b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and (c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: February 22, 2022
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Virginia Ammendola, Stefano Colloca, Riccardo Cortese, Fabiana Grazioli, Alfredo Nicosia, Alessandra Vitelli
  • Patent number: 11214599
    Abstract: The present invention relates to novel adenovirus strains with an improved seroprevalence. In one aspect, the present invention relates to isolated polypeptides of adenoviral capsid proteins such as hexon, penton and fiber protein and fragments thereof and polynucleotides encoding the same. Also provided is a vector comprising the isolated polynucleotide according to the invention and adenoviruses comprising the isolated polynucleotides or polypeptides according to the invention and a pharmaceutical composition comprising said vector, adenovirus, polypeptide and/or polynucleotide. The invention also relates to the use of the isolated polynucleotides, the isolated polypeptides, the vector, the adenoviruses and/or the pharmaceutical composition for the therapy or prophylaxis of a disease.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: January 4, 2022
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Stefano Colloca, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Maria Ambrosio
  • Publication number: 20210269486
    Abstract: The invention provides adenoviral vectors comprising transgenes encoding Lyssaviral antigens. The vectors can be used to produce vaccines for the prophylaxis, amelioration and treatment of diseases caused by Lyssaviral diseases, e.g., rabies.
    Type: Application
    Filed: December 8, 2017
    Publication date: September 2, 2021
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Virginia AMMENDOLA, Stefaano COLLOCA, Alessandra VITELLI, Benjamin Wizel
  • Publication number: 20210246468
    Abstract: The present invention relates to isolated polynucleotide and polypeptide sequences derived from novel chimpanzee adenovirus ChAd157, as well as to recombinant polynucleotides, vectors, adenoviruses, cells and compositions comprising said polynucleotide and polypeptide sequences.
    Type: Application
    Filed: June 11, 2019
    Publication date: August 12, 2021
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Virginia AMMENDOLA, Stefania CAPONE, Stefano COLLOCA, Antonella FOLGORI, Rosella MERONE
  • Publication number: 20210189421
    Abstract: Replication competent simian adenoviral vectors are provided for the delivery of exogenous immunogens. Vectors of the invention demonstrate superior replication and expression of exogenous immunogens. They are useful as prophylactic and therapeutic vaccines as well as in gene therapy.
    Type: Application
    Filed: October 16, 2018
    Publication date: June 24, 2021
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Virginia AMMENDOLA, Stefano COLLOCA, Alessandra VITELLI
  • Publication number: 20210154290
    Abstract: The present invention relates to immunogenic compositions and combinations thereof which may find use in immunisation regimens for the treatment of chronic hepatitis B. An immunogenic composition comprises a replication-defective chimpanzee adenoviral (ChAd) vector comprising polynucleotides encoding HBs, HBc human invariant chain (hIi) fused to the HBc. Another immunogenic composition comprises a Modified Vaccinia Virus Ankara (MVA) vector comprising polynucleotides encoding HBs and HBc. Another immunogenic composition comprises recombinant HBs, C-terminal truncated recombinant HBc and an adjuvant containing MPL and QS-21.
    Type: Application
    Filed: December 14, 2018
    Publication date: May 27, 2021
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Virginia AMMENDOLA, Babak BAYAT, Clarisse LORIN, Ventzislav Bojidarov VASSILEV, Alessandra VITELLI
  • Publication number: 20210069322
    Abstract: There is provided a method of treating chronic hepatitis B infection (CHB) in a human, comprising the steps of: a) administering to the human a composition comprising a replication-defective chimpanzee adenoviral (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); b) administering to the human a composition comprising a Modified Vaccinia Virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); and c) administering to the human a composition comprising a recombinant hepatitis B surface antigen (HBs), recombinant hepatitis B virus core antigen (HBc) and an adjuvant.
    Type: Application
    Filed: December 14, 2018
    Publication date: March 11, 2021
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Virginia AMMENDOLA, Babak BAYAT, Clarisse LORIN, Ventzislav Bojidarov VASSILEV, Alessandra VITELLI
  • Publication number: 20210060150
    Abstract: There is provided adenoviral vectors encoding a mycobacterial antigen derived from a chimp adenovirus, and to related aspects.
    Type: Application
    Filed: August 6, 2020
    Publication date: March 4, 2021
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Stefano COLLOCA, Virginia AMMENDOLA, Fabiana GRAZIOLI, Alessandra VITELLI, Alfredo NICOSIA, Riccardo CORTESE
  • Publication number: 20200149069
    Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).
    Type: Application
    Filed: January 24, 2020
    Publication date: May 14, 2020
    Applicants: The Government of the United States of America as Represented by the Secretary of the Department of, GlaxoSmithKline Biologicals SA
    Inventors: Nancy J. Sullivan, Gary J. Nabel, Clement Asiedu, Cheng Cheng, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Stefano Colloca
  • Publication number: 20200140886
    Abstract: There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of: (a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, (b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and (c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.
    Type: Application
    Filed: June 10, 2016
    Publication date: May 7, 2020
    Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA
    Inventors: Virginia AMMENDOLA, Stefano COLLOCA, Riccardo CORTESE, Fabiana GRAZIOLI, Alfredo NICOSIA, Alessandra VITELLI
  • Publication number: 20200102352
    Abstract: The present invention relates to novel adenovirus strains with an improved seroprevalence. In one aspect, the present invention relates to isolated polypeptides of adenoviral capsid proteins such as hexon, penton and fiber protein and fragments thereof and polynucleotides encoding the same. Also provided is a vector comprising the isolated polynucleotide according to the invention and adenoviruses comprising the isolated polynucleotides or polypeptides according to the invention and a pharmaceutical composition comprising said vector, adenovirus, polypeptide and/or polynucleotide. The invention also relates to the use of the isolated polynucleotides, the isolated polypeptides, the vector, the adenoviruses and/or the pharmaceutical composition for the therapy or prophylaxis of a disease.
    Type: Application
    Filed: December 11, 2019
    Publication date: April 2, 2020
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Stefano Colloca, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Maria Ambrosio
  • Patent number: 10584355
    Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: March 10, 2020
    Assignees: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Nancy J. Sullivan, Gary J Nabel, Clement Asiedu, Cheng Cheng, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Stefano Colloca